BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23823982)

  • 21. Transcriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodies.
    Vialatte de Pémille C; Berzero G; Small M; Psimaras D; Giry M; Daniau M; Sanson M; Delattre JY; Honnorat J; Desestret V; Alentorn A
    Br J Cancer; 2018 Jul; 119(1):105-113. PubMed ID: 29899393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Restricted IgG1 subclass of anti-Yo antibodies in paraneoplastic cerebellar degeneration.
    Amyes E; Curnow J; Stark Z; Corlett L; Sutton I; Vincent A
    J Neuroimmunol; 2001 Mar; 114(1-2):259-64. PubMed ID: 11240040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytotoxic T cells against a peptide of Yo protein in patients with paraneoplastic cerebellar degeneration and anti-Yo antibody.
    Tanaka M; Tanaka K; Tokiguchi S; Shinozawa K; Tsuji S
    J Neurol Sci; 1999 Sep; 168(1):28-31. PubMed ID: 10500270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with gastric adenocarcinoma.
    Meglic B; Graus F; Grad A
    J Neurol Sci; 2001 Apr; 185(2):135-8. PubMed ID: 11311295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paraneoplastic cerebellar degeneration with anti-Yo antibodies associated with metastatic uveal melanoma.
    Valpione S; Zoccarato M; Parrozzani R; Pigozzo J; Giometto B; Laveder F; Aliberti C; Chiarion-Sileni V
    J Neurol Sci; 2013 Dec; 335(1-2):210-2. PubMed ID: 24035275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Paraneoplastic cerebellar degeneration--characterization of anti-Yo antibody and underlying cancer].
    Tanaka K; Tanaka M; Onodera O; Tsuji S
    Rinsho Shinkeigaku; 1995 Jul; 35(7):770-4. PubMed ID: 8777801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Paraneoplastic cerebellar degeneration associated with ovarian cancer: anti-Yo immunoreactivity in autoptic cerebellum and ovarian carcinoma].
    Bartos A; Stourac P; Rusina R; Sejdová M; Velenská Z
    Nervenarzt; 2002 Oct; 73(10):995-8. PubMed ID: 12376889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration.
    Peter E; Treilleux I; Wucher V; Jougla E; Vogrig A; Pissaloux D; Paindavoine S; Berthet J; Picard G; Rogemond V; Villard M; Vincent C; Tonon L; Viari A; Honnorat J; Dubois B; Desestret V
    Neurol Neuroimmunol Neuroinflamm; 2022 Sep; 9(5):. PubMed ID: 35821104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration associated with cognitive affective syndrome in a patient with breast cancer: a case report and literature review.
    Le May M; Dent S
    Curr Oncol; 2018 Dec; 25(6):e585-e591. PubMed ID: 30607127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Importance of plasmapheresis in the treatment of paraneoplastic cerebellar degeneration].
    Basić-Jukić N; Kes P; Basić-Kes V; Brunetta B
    Acta Med Croatica; 2004; 58(1):63-6. PubMed ID: 15125396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paraneoplastic cerebellar syndromes associated with antibodies against Purkinje cells.
    Schwenkenbecher P; Chacko L; Pul R; Sühs KW; Wegner F; Wurster U; Stangel M; Skripuletz T
    Int J Neurosci; 2018 Aug; 128(8):721-728. PubMed ID: 29199513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Case Report: A False Negative Case of Anti-Yo Paraneoplastic Myelopathy.
    Bartley CM; Parikshak NN; Ngo TT; Alexander JA; Zorn KC; Alvarenga BA; Kang MK; Pedriali M; Pleasure SJ; Wilson MR
    Front Neurol; 2021; 12():728700. PubMed ID: 34744969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional analysis of CD8+ T cell responses to the onconeural self protein cdr2 in patients with paraneoplastic cerebellar degeneration.
    Carpenter EL; Vance BA; Klein RS; Voloschin A; Dalmau J; Vonderheide RH
    J Neuroimmunol; 2008 Jan; 193(1-2):173-82. PubMed ID: 18053582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: implications for neuronal and tumor cell survival.
    Okano HJ; Park WY; Corradi JP; Darnell RB
    Genes Dev; 1999 Aug; 13(16):2087-97. PubMed ID: 10465786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteasome antibodies in paraneoplastic cerebellar degeneration.
    Storstein A; Knudsen A; Vedeler CA
    J Neuroimmunol; 2005 Aug; 165(1-2):172-8. PubMed ID: 15964637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autoantibodies in paraneoplastic cerebellar degeneration bind to cytoplasmic antigens of Purkinje cells in humans, rats and mice and are of multiple immunoglobulin classes.
    Smith JL; Finley JC; Lennon VA
    J Neuroimmunol; 1988 Apr; 18(1):37-48. PubMed ID: 3346369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paraneoplastic neurological syndromes associated with Yo, Hu, and Ri autoantibodies.
    Bradwell AR
    Clin Rev Allergy Immunol; 2000 Aug; 19(1):19-29. PubMed ID: 11064823
    [No Abstract]   [Full Text] [Related]  

  • 38. CDR2 and CDR2L Yo Antigens in Paraneoplastic Cerebellar Degeneration.
    Greenlee JE; Carlson NG
    Ann Neurol; 2020 Aug; 88(2):428. PubMed ID: 32445212
    [No Abstract]   [Full Text] [Related]  

  • 39. Reply to "CDR2 and CDR2L Yo Antigens in Paraneoplastic Cerebellar Degeneration".
    Kråkenes T; Herdlevaer I; Raspotnig M; Haugen M; Schubert M; Vedeler C
    Ann Neurol; 2020 Aug; 88(2):429. PubMed ID: 32445220
    [No Abstract]   [Full Text] [Related]  

  • 40. Multi-omics profiling reveals dysregulated ribosome biogenesis and impaired cell proliferation following knockout of CDR2L.
    Solheim ET; Gerking Y; Kråkenes T; Herdlevær I; Birkeland E; Totland C; Dick F; Vedeler CA
    BMC Cancer; 2024 May; 24(1):645. PubMed ID: 38802745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.